The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Best practices for safely delivering bispecific antibodies in lymphoma
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, outlines best practices for initiating and monitoring bispecific antibody therapy in lymphoma, covering patient assessment, prevention and recognition of CRS and ICANS, infection prophylaxis, and patient education to support safe outpatient treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
